Customer Center
Login | Register


Nanosphere | Verigene® Bloodstream Infection Tests | Verigene® Gram-Positive Blood Culture Test

The Verigene® Gram-Positive Blood Culture Test (BC-GP) identifies genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood culture bottles

While conventional microbiological methods may require 2-4 days to produce bacterial identification and susceptibility results, Verigene BC-GP provides results within 2.5 hours of blood culture positivity.


Gram-positive bacteria are also a common source of contamination during blood draws, which results in clinically-irrelevant positive blood cultures. This can lead to inappropriate antimicrobial use1 and wasted time and cost. Patients with contaminated blood culture bottles are often presumptively treated for bloodstream infections for several days until the organism can be identified as a contaminant using conventional biochemical methods.

Gram-Positive Blood Culture Test Specifications


Targets U.S./FDA-Cleared Outside U.S.
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus anginosus Group
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Enterococcus faecium
Staphylococcus spp.
Streptococcus spp.
Micrococcus spp.  
Listeria spp.
mecA (methicillin)
vanA (vancomycin)
vanB (vancomycin)


Key Features
Automation Sample to Result
Instrumentation Verigene Reader and Processor SP
Workflow On-Demand and Scalable
Sample Type Positive Blood Culture Bottle
Hands-On Time <5 minutes
Run Time <2.5 hours
†For use with all commercially available continuous monitoring blood culture bottles; see Verigene BC-GP package insert for details.


Learn how the Verigene® System provides cost-effective bacterial identification and antibiotic resistance determination directly from positive blood culture bottles up to 48 hours faster than conventional methods.
Read More


Learn how the Verigene Gram-Negative Blood Culture Test (BC-GN) can provide results within two hours of blood culture positivity.
Read More

  1. von Eiff C, Herrmann M, Peters G. 1995. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Ag Chemo. 39:268-270.


For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

Intended Use

The Verigene® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) performed using the sample-to-result Verigene System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection (BSI). BC-GP is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria.

BC-GP detects and identifies the following bacterial genera and species: Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium, Listeria spp.

In addition, BC-GP detects the mecA resistance marker, inferring mecA-mediated methicillin resistance, and the vanA and vanB resistance markers, inferring vanA/vanB-mediated vancomycin resistance. In mixed growth, BC-GP does not specifically attribute van-mediated vancomycin resistance to either E. faecalis or E. faecium, or mecA-mediated methicillin resistance to either S. aureus or S. epidermidis.

BC-GP is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identification of organisms not detected by BC-GP, differentiation of mixed growth, association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.